Abstract
In a preliminary study rubidomycin was found capable of inducing remission in adults with acute leukaemia, the remission rate in acute myeloblastic leukaemia comparing favourably with that achieved with previous forms of therapy. Marrow aplasia and cardio-toxicity occurred in a number of patients. Supportive measures during the former and early recognition by frequent electrocardiography can do much to mitigate these toxic effects.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bernard J., Jacquillat C., Boiron M., Najean Y., Seligmann M., Tanzer J., Weil M., Lortholary P. Essai de traitement des leucémies aiguës lymphoblastiques et myéloblastiques par un antibiotique nouveau: la rubidomycine (13,057 RP). Etude de 61 observations. Presse Med. 1967 Apr 22;75(19):951–955. [PubMed] [Google Scholar]
- Mathé G., Hayat M., Schwarzenberg L., Amiel J. L., Schneider M., Cattan A., Schlumberger J. R., Jasmin C. Acute lymphoblastic leukaemia treated with a combination of prednisone, vincristine, and rubidomycin. Value of pathogen-free rooms. Lancet. 1967 Aug 19;2(7512):380–382. doi: 10.1016/s0140-6736(67)92004-1. [DOI] [PubMed] [Google Scholar]